Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
Sign Up to like & getrecommendations! Published in 2022 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002047
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug for axSpA patients. Failed to NSAIDs therapy, tumor necrosis factor (TNF)-a inhibitor (TNFi) was suggested in the treatment strategy of axSpA. But 30% of axSpA… read more here.
Keywords: real life; axial spondyloarthritis; life effectiveness; safety secukinumab ... See more keywords